11/16/2010 10:00:28 AM
RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, Amherst (UMass), have received a Phase 2 Small Business Technology Transfer (STTR) contract in the amount of $750,000. This contract will allow PolyMedix to conduct further testing on antimicrobial compounds which PolyMedix identified under the initial Phase 1 contract. These compounds are being developed to specifically treat multi-drug resistant biofilm-embedded bacteria. This award represents the 15th grant or research contract received to date by PolyMedix.
comments powered by